127P Waning Effect of Adjuvant EGFR TKIs in Resected EGFR-mutated (Egfr-M) NSCLC: A Systematic Review and Meta-Analysis of Randomized Clinical Trials (Rcts)

Osimertinib has been approved as adjuvant (adj) therapy in resected EGFR-m non-small cell lung cancer (NSCLC) based on results of the ADAURA trial. Despite the improvement in both disease-free survival (DFS) and overall survival (OS), it is still unclear if adj TKI result in a delay of recurrence rather than cure.